SCHEMBL3242896

SCHEMBL3242896

O=C(NCc1ccc(F)c(Cl)c1)c1ccc(C(=O)N2CCCCC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.54
ALDH1A1 P00352 4/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
KLKB1 P03952 1/20 0.51
KLK1 P06870 1/20 0.51
HSD11B1 P28845 2/20 0.49
LIPG Q9Y5X9 1/20 0.49
HPGD P15428 5/20 0.48
RAB9A P51151 2/20 0.48
NPC1 O15118 1/20 0.48
S1PR3 Q99500 1/20 0.48
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CYP2C9 P11712 1/20 0.46
NAMPT P43490 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3237671 0.89 HPGD (0.59) MAPTALDH1A1L3MBTL1KLKB1KLK1
SCHEMBL3242897 0.86 MAPT (0.54) MAPTALDH1A1L3MBTL1HSD11B1HPGD
SCHEMBL3259879 0.85 MAPT (0.70) MAPTALDH1A1L3MBTL1KLKB1KLK1
SCHEMBL3241841 0.83 HSD11B1 (0.59) MAPTALDH1A1L3MBTL1KLKB1KLK1
SCHEMBL3808704 0.79 HPGD (0.64) MAPTALDH1A1L3MBTL1KLKB1KLK1
SCHEMBL4720578 0.78 MMP13 (0.52) HSD11B1LMNANAMPT
SCHEMBL2653348 0.78 HPGD (0.73) MAPTALDH1A1HSD11B1HPGDMEN1
SCHEMBL14258950 0.75 MMP13 (0.56) MAPTALDH1A1L3MBTL1KLKB1KLK1
SCHEMBL2075037 0.75 HPGD (0.68) MAPTALDH1A1HSD11B1HPGDMEN1
SCHEMBL3237674 0.75 HPGD (0.59) MAPTALDH1A1L3MBTL1HSD11B1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 MAPT 3110/4885ALDH1A1 1588/4885L3MBTL1 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.